Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2018 Jun;32(3):417-431. doi: 10.1016/j.hoc.2018.01.005. Epub 2018 Mar 9.

Cancer-Related Neuropathic Pain: Review and Selective Topics.

Author information

1
Department of Palliative Care, Geisinger Medical Center, 100 North Academy Avenue, Danville, PA 17822, USA. Electronic address: mdavis2@geisinger.edu.

Abstract

Neuropathic pain is the result of neuroplastic and neuroinflammatory changes from trauma or diseases that damage the somatosensory system. Cancer-related neuropathic pain is caused by treatment, cancer, or paraneoplastic reactions to cancer. Approximately 30% of patients with cancer have neuropathic pain, mostly mixed nociceptive and neuropathic pain. History, physical examination, quantitative sensory testing, skin punch biopsies, and functional MRIs help to divide pain into phenotypes that may facilitate analgesic choices. Guidelines for treating cancer-related neuropathic pain are not consistent and are highly dependent on trials in patients without cancer. Combinations of analgesics are promising, whereas evidence for cannabinoids is meager.

KEYWORDS:

Analgesics; Cannabinoids; Neuroinflammation; Neuropathic; Neuroplasticity; Pain

PMID:
29729778
DOI:
10.1016/j.hoc.2018.01.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center